A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study-Reference-Cited by-同舟云学术

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

Published:2018-11-07 Issue:2 Volume:20 Page:192-200
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Gamucci Teresa¹²,Pizzuti Laura³,Natoli Clara⁴,Mentuccia Lucia¹,Sperduti Isabella⁵,Barba Maddalena³⁶,Sergi Domenico³,Iezzi Laura⁴,Maugeri-Saccà Marcello³⁶,Vaccaro Angela¹,Magnolfi Emanuela¹,Gelibter Alain⁷,Barchiesi Giacomo⁷,Magri Valentina⁷,D’Onofrio Loretta⁸,Cassano Alessandra⁹,Rossi Ernesto⁹,Botticelli Andrea¹⁰,Moscetti Luca¹¹,Omarini Claudia¹¹^ORCID,Fabbri Maria Agnese¹²,Scinto Angelo Fedele¹³,Corsi Domenico¹³,Carbognin Luisa¹⁴,Mazzotta Marco¹⁰,Bria Emilio¹⁴^ORCID,Foglietta Jennifer¹⁵,Samaritani Riccardo¹⁶,Garufi Carlo¹⁷,Mariani Luciano¹⁸,Barni Sandro¹⁹,Mirabelli Rosanna²⁰,Sarmiento Roberta²¹,Graziano Vincenzo²²²³,Santini Daniele⁸,Marchetti Paolo¹⁰,Tonini Giuseppe⁸,Di Lauro Luigi³,Sanguineti Giuseppe²⁴,Paoletti Giancarlo³,Tomao Silverio⁷,De Maria Ruggero²⁵,Veltri Enzo²⁶,Paris Ida²⁷,Giotta Francesco²⁸,Latorre Agnese²⁸,Giordano Antonio²⁹,Ciliberto Gennaro⁶,Vici Patrizia³

Affiliation:

1. Medical Oncology Unit, ASL Frosinone, Frosinone, Italy

2. Medical Oncology, Sandro Pertini Hospital, Roma, Italy

3. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

4. Department of Medical, Oral and Biotechnological Sciences, Centro Scienze dell’Invecchiamento e Medicina Traslazionale -CeSI-MeT, Chieti, Italy

5. Bio-Statistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

6. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy

7. Medical Oncology Unit, Policlinico Umberto I, Rome, Italy

8. Department of Oncology, University Campus Biomedico of Rome, Rome, Italy

9. Department of Medical Oncology, Policlinico Universitario “A. Gemelli”, Rome, Italy

10. Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, Azienda Ospedaliera Sant’Andrea, Rome, Italy

11. Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy

12. Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy

13. Medical Oncology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy

14. U.O.C. Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

15. Department of Medical Oncology, University of Perugia, Santa Maria della Misericordia Hospital, Perugia, Italy

16. Medical Oncology Unit, “Regina Margherita” Hospital, Rome, Italy

17. Division of Medical Oncology, Pescara Hospital, Pescara, Italy

18. HPV Unit, Department of Gynaecologic Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

19. Department of Oncology, Oncology Unit, ASST Bergamo Ovest, Treviglio, Italy

20. Department of Hematology & Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy

21. Oncology Unit, San Filippo Neri Hospital, Rome, Italy

22. Medical Oncology Unit, SS Annunziata Hospital, Chieti, Italy

23. Breast Medical Oncology Unit, G. Bernabeo Hospital, Ortona, Italy

24. Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

25. Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy

26. Oncology Unit, S. Maria Goretti Hospital, Latina, Italy

27. Gynecology Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy

28. Department of Medical Oncology, “Giovanni Paolo II” Institute, Bari, Italy

29. Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA, USA

Funder

This work was supported by Consorzio Interuniversitario Nazionale per la Bio-Oncologia

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2018.1523095

Reference26 articles.

1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

2. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

3. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group